X
skip to main content
Logo
media conference

Press Releases

  • September 06, 2017

    Subtype-specific alterations in BCL2 linked to poor post-treatment outcomes in non-Hodgkin lymphoma

    Subtype-specific alterations in a driver gene for non-Hodgkin lymphoma (BCL2) is strongly associated with poor patient outcomes after treatment.

  • September 06, 2017

    Discovery of seven new ovarian cancer subtypes opens door for more targeted treatments

    The discovery of seven new genetic subtypes of ovarian cancer may lead to targeted treatments for women diagnosed with this disease, including those with the most malignant form.

  • September 05, 2017

    Three 2017 PPG awards announced for cutting-edge projects in leukemia, oncolytic viruses, nanoparticle imaging

    The Terry Fox Research Institute has invested nearly $21.5-million to renew three 2017 Terry Fox New Frontiers Program Project Grants (PPGs).

  • June 30, 2017

    Canadian hero Terry Fox’s cancer research legacy lives on: VICE Sports

    Two features articles published by VICE Sports for Canada 150 are calling Terry Fox the most important athlete in Canadian history whose cancer research legacy lives on.

  • June 30, 2017

    Lung cancer screening may save both lives and money, study suggests

    New research from a TFRI-funded team suggests screening for lung cancer could save money – and lives – especially if it also identifies other tobacco-related conditions in high-risk individuals.

  • June 22, 2017

    One in two Canadians will get cancer, but research offers hope for cures

    Terry’s dream was to fund research to cure cancer, and he inspired us with that dream. We believe that it is through research that cures to cancer will be found, and survival rates for even the most challenging cancers will continue to increase.

  • May 29, 2017

    TFRI's Dr. Victor Ling recognized for breakthrough in fighting drug-resistant cancers

    Dr. Victor Ling, president and scientific director of The Terry Fox Research Institute, has been recognized by The Vancouver Sun for his breakthrough in fighting drug-resistant cancers.

  • May 24, 2017

    MATE2 expression a negative predictive biomarker to metformin’s efficacy in cancer treatment, study suggests

    The drug metformin is typically used to treat Type 2 diabetes, and some cancer patients have shown improved outcome when given the drug. A recent study by TFRI’s hypoxia group sheds new light on biomarkers that may indicate the drug’s efficacy in patients.

  • May 24, 2017

    Groundbreaking study sheds light on signaling molecules that control human hematopoietic stem cell survival and growth

    TFRI’s long-funded program project on human leukemia has made groundbreaking progress in the quest to expand human blood stem cells for therapeutic purposes.

  • May 24, 2017

    Novel 17-gene test predicts if patients with aggressive leukemia will respond to treatment or not

    What if there was a way to predict if leukemia patients would respond to standard treatment or not? A TFRI-funded team has developed a novel, 17-gene signature test from leukemia stem cells (LSCs) that determines just that.

  • May 24, 2017

    Canadian study identifies predictive genomic signature for high-risk prostate cancer

    Understanding why some prostate cancer tumours are indolent while others eventually kill patients is the focus of many within the global cancer research community. A top Canadian research team has provided new answers with the potential to change the way aggressive tumours are treated and, importantly, improve cure rates.

  • May 24, 2017

    Complement inhibitors decrease neutralization of some oncolytic viruses, increase treatment efficacy

    The use of oncolytic viruses to stimulate a patient’s immune system as well as directly kill tumour cells is a novel approach to eradicating cancer, but antibodies that permanently inactivate the virus are often generated that counter treatment efficacy. An Ottawa-based lab has come up with a way of countering this problem by using a complement inhibitor that prevents the virus’ neutralization, thereby ensuring viral vectors reach their target.

  • May 18, 2017

    B.C. team study detects rare ovarian cancer mutation in ctDNA of patients

    The finding by a B.C. team studying rare and forme fruste tumours is important in that it may help to identify women at risk of relapse for the disease, as well as to provide a non-invasive way to monitor patients in follow-up.

  • May 17, 2017

    Terry Fox Foundation is media outlet’s top pick for donating to cancer research

    An article published in The National Post in mid-May has identified the Terry Fox Foundation as one of the best places to donate to cancer research in Canada.

  • April 25, 2017

    Four 2017 New Investigator award recipients announced

    Awards to four New Investigators were recently made, with each award valued at $450,000 for a term of three years. Recipients are: Dr. Housheng Hansen He (UHN), Dr. Frédérick Mallette (UdeM), and Dr. Peter Stirling (BC Cancer Agency), and Dr. Trevor Pugh.

Back to Top